Neovasc Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Neovasc Inc (NVCN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Neovasc Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 3M vs 0M combined for tracked competitors (112.5% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Profitability: Its -977.0% net margin compares with -1,881.5% for the peer group.
- Peer revenue share: Neovasc Inc accounted for 95.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NVCN Sales vs. its Competitors, Q4 2021
With a net margin of -977.04 %, Neovasc Inc achieved higher profitability than its competitors (-1,881.48 %).
Neovasc Inc generated 94.97 % of the combined sales of its peer group.
API endpoints for this dataset
Neovasc Inc vs. its Competitors, Q4 2021
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Neovasc Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Neovasc Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Neovasc Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (119) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Neovasc Inc's competitor groups requires a Commercial License.
Neovasc Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Neovasc Inc | - | Yes | Yes | No |
| Competitors combined (1) | - | - | - | |
| High-Confidence Competitors (133) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NVCN Stock Performance relative to its Competitors
NVCN Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Titan Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Neovasc Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Neovasc Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Neovasc Inc | 1,891.11 | 2.55 |
| Titan Pharmaceuticals Inc | 4.91 | -0.28 |
| SUBTOTAL | 1,896.02 | 2.26 |
Sources: Neovasc Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Neovasc Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Neovasc Inc's Competitors Named by the Company
Competitive relationships identified from Neovasc Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Medtronic plc | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Angiodynamics Inc | Company report | 85% |
| Intuitive Surgical Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Encision Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| United Health Products Inc | Company report | 85% |
| Co diagnostics Inc | Company report | 85% |
| Catheter Precision Inc | Company report | 85% |
| Integra Lifesciences Holdings Corp | Company report | 85% |
| Koninklijke Philips Nv | Company report | 85% |
| Globus Medical Inc | Company report | 85% |
| Bioventus Inc | Company report | 85% |
| Acutus Medical Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Cardiovascular Systems, Inc. | Company report | 85% |
| Inspiremd Inc | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Stryker Corp | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Enovis Corp | Company report | 85% |
| Biodexa Pharmaceuticals Plc | Company report | 85% |
| Monogram technologies inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Paragon 28 inc | Company report | 85% |
| Addex Therapeutics Ltd | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Apexigen Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Neovasc Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Neovasc Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Neovasc Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Neovasc Inc | 1,891 | - | - |
| Titan Pharmaceuticals Inc | 5 | -71,000 | -701,250 |
| PEERS TOTAL | 5 | -71,000 | -701,250 |
Neovasc Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 78.19 % | 46.85 % (avg) | +31.3 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.47 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 6.44 % | 7.10 % (avg) | -0.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Neovasc Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 37.0x | - |
| EV / EBITDA | - | 17.4x | - |
| P/B | 0.8x | 4.6x | -3.8x |
| Return on Equity | -47.65 % | industry aggregate | -56.98 % |
| Return on Invested Capital | -27.27 % | -6.54 % (avg) | -20.73 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Neovasc Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue Growth | 19.60 % | -6.44 % | 30.14 % |
| Operating Margin | - | - | - |
| Return on Invested Capital | - | -756.56 % | -27.27 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Neovasc Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 6.44 % vs industry average 7.10 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Neovasc Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Neovasc Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Neovasc Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Return on equity 57.0 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Neovasc Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Neovasc Inc | 10.35 | 11.08 | - |
| Titan Pharmaceuticals Inc | 7.86 | 8.40 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Neovasc Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Neovasc Inc | Q4 2021 | +30.1 % | - |
| Titan Pharmaceuticals Inc | Q2 2025 | - | - |
| PEERS TOTAL | +30.1 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Neovasc Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Neovasc Inc | Q4 2021 | +24.5 % | -52.0 % |
| Titan Pharmaceuticals Inc | Q2 2025 | - | - |
Neovasc Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Neovasc Inc | - | - | - |
| Titan Pharmaceuticals Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Neovasc Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Neovasc Inc | - | 742.37 |
| Titan Pharmaceuticals Inc | - | - |
| PEERS AVERAGE | - | 837.68 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.